The biomedical field has made tremendous strides in turning many cancers into survivable diseases. However, in the years and decades following treatment, many survivors have a significantly higher incidence of severe chronic illness – often an unintended consequence of the drugs and therapies that saved their lives. Effects can include cardiac dysfunction or failure, pulmonary problems, neurological issues, liver toxicity, and endocrine disorders (Cleeland et al 2012). Adverse impacts on patient quality of life are not unique to any one oncologic drug class or therapeutic approach. Both traditional small molecule therapies and radio-therapy as well as novel immunotherapies may contribute. These effects can impact the survivor’s quality of life including general health status, ability to maintain employment, relationships with friends and families, among others. Some effects can be lethal. For example, children and adults given doxorubicin therapy for a variety of malignant tumors have experienced heart failure later in life. Despite the opportunity to do better, funding for research in this critical arena has been limited.
The THRIVE program seeks to chart new futures for cancer survivors by Making Patient Quality of Life an Active Research Priority. This program fills a critical gap in funding for foundational research in support of future protective therapies, mitigation strategies and a next generation of drugs that will enhance the ability for cancer survivors to THRIVE.
What is it?
THRIVE offers funding for basic science, clinical, and translational research that enhances our ability to predict when and how adverse effects may occur in patients who have received cancer treatment and supports the development of approaches to avoid or lessen these effects. By providing researchers with both seed funding and access to critical networks, THRIVE will enhance the visibility of the patient need, the value of the research, and the reasons that larger funding entities might elect to incorporate these research streams into future funding priorities.
This unique program focuses on innovative cross-disciplinary research with defined impact for patients. THRIVE gives preference to those innovative research projects that engage both non-clinical AND clinical scientists in the research project design and/or implementation. We believe that research at the translational boundary can make significant impact on the science and patients. This research will advance our:
- Fundamental understanding of cancer drug or therapy-related toxicity;
- Ability to identify and translate critical biomarkers of toxicity;
- Models (in vivo, in vitro, in silico) of pediatric or adult drug exposure that predict early or impending toxicities; and/or
- Understanding of the role of protective co-therapies or modified exposure protocols on the onset of therapy-induced damage.
Identification of novel protective therapies or dosing-strategies
How can I help?
Our ability to support research depends upon access to financial resources. This program offers the opportunity for funders to synergize their contribution with existing grant funding from both public and private sector partners and be recognizing as supporting partners. 100% of your funding support will transfer directly to the awardees. Join us in innovating translational research, and improving quality of life after cancer.